BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc.verified

BMRN

Price:

$66.27

Market Cap:

$12.63B

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcu...[Read more]

Industry

Biotechnology

IPO Date

1999-07-26

Stock Exchange

NASDAQ

Ticker

BMRN

The Enterprise Value as of December 2024 (TTM) for BioMarin Pharmaceutical Inc. (BMRN) is 12.56B

According to BioMarin Pharmaceutical Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 12.56B. This represents a change of -21.94% compared to the average of 16.09B of the last 4 quarters.

BioMarin Pharmaceutical Inc. (BMRN) Historical Enterprise Value (quarterly & annually)

How has BMRN Enterprise Value performed in the past?

The mean historical Enterprise Value of BioMarin Pharmaceutical Inc. over the last ten years is 16.20B. The current 12.56B Enterprise Value has changed 7.65% with respect to the historical average. Over the past ten years (40 quarters), BMRN's Enterprise Value was at its highest in in the June 2020 quarter at 22.92B. The Enterprise Value was at its lowest in in the September 2019 quarter at 12.50B.

Quarterly (TTM)
Annual

Average

16.20B

Median

16.21B

Minimum

12.95B

Maximum

19.53B

BioMarin Pharmaceutical Inc. (BMRN) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of BioMarin Pharmaceutical Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 32.41%

Maximum Annual Enterprise Value = 19.53B

Minimum Annual Increase = -17.64%

Minimum Annual Enterprise Value = 12.95B

Quarterly (TTM)
Annual
YearEnterprise ValueChange
202318.45B-5.53%
202219.53B17.33%
202116.65B2.25%
202016.28B4.71%
201915.55B0.88%
201815.41B-4.44%
201716.13B15.01%
201614.03B-17.64%
201517.03B31.54%
201412.95B32.41%

BioMarin Pharmaceutical Inc. (BMRN) Average Enterprise Value

How has BMRN Enterprise Value performed in the past?

The current Enterprise Value of BioMarin Pharmaceutical Inc. (BMRN) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

18.21B

5-year avg

17.29B

10-year avg

16.20B

BioMarin Pharmaceutical Inc. (BMRN) Enterprise Value vs. Peers

How is BMRN’s Enterprise Value compared to its peers?

BioMarin Pharmaceutical Inc.’s Enterprise Value is less than Seagen Inc. (42.84B), less than Alnylam Pharmaceuticals, Inc. (31.45B), greater than Exelixis, Inc. (9.50B), greater than Halozyme Therapeutics, Inc. (7.35B), greater than Arrowhead Pharmaceuticals, Inc. (2.87B), greater than Incyte Corporation (12.19B), greater than Ionis Pharmaceuticals, Inc. (6.81B), greater than Apellis Pharmaceuticals, Inc. (4.20B), greater than Vaxcyte, Inc. (9.83B), greater than Liquidia Corporation (766.57M), greater than Legend Biotech Corporation (6.11B), greater than Bio-Techne Corporation (11.77B), greater than Mereo BioPharma Group plc (445.16M), greater than Blueprint Medicines Corporation (6.12B), greater than Agios Pharmaceuticals, Inc. (1.82B), greater than Day One Biopharmaceuticals, Inc. (859.59M), greater than IVERIC bio, Inc. (5.13B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), greater than Karuna Therapeutics, Inc. (12.43B),

Build a custom stock screener for BioMarin Pharmaceutical Inc. (BMRN) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like BioMarin Pharmaceutical Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

BioMarin Pharmaceutical Inc. (BMRN) and other stocks custom spreadsheet templates

The easiest way to analyze a company like BioMarin Pharmaceutical Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is BioMarin Pharmaceutical Inc.'s Enterprise Value?

What is the highest Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN)?

What is the 3-year average Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN)?

What is the 5-year average Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN)?

How does the current Enterprise Value for BioMarin Pharmaceutical Inc. (BMRN) compare to its historical average?